Ulcerated Necrobiosis Lipoidica Market

DelveInsight’s ‘Ulcerated Necrobiosis Lipoidica -Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Ulcerated Necrobiosis Lipoidica, historical and forecasted epidemiology as well as the Ulcerated Necrobiosis Lipoidica market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Ulcerated Necrobiosis Lipoidica market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Ulcerated Necrobiosis Lipoidica market size from 2019 to 2032. The Report also covers current Ulcerated Necrobiosis Lipoidica treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Ulcerated Necrobiosis Lipoidica Disease Understanding and Treatment Algorithm

Ulcerated Necrobiosis Lipoidica Overview

Necrobiosis lipoidica (NL) is a granulomatous disease of unknown cause in which degeneration of dermal collagen occurs. Many of the NL affected patients can lead to ulcerations, which can impair the quality of life and are also very difficult to treat. It can occur in both Type 1 and 2 diabetes, affecting the majority of patients with diabetes. NL usually appears as patches or lesions on the lower legs or shins and can also appear elsewhere on the body – such as on the upper legs, hands, arms, torso, face, or scalp – though this is rare.

 

People with NL may notice one or more shiny, raised, flushed patches of skin on the lower legs. These may also be itchy or painful, and the centers of the patches can become pale with visible blood vessels. The cause of NL is unknown. There are various theories for its occurrence. The most common theories among it involve elements of a vascular disturbance involving immune complex deposition or microangiopathic changes leading to collagen degeneration.

 

Ulcerated Necrobiosis Lipoidica Diagnosis

Although the diagnosis often is based on clinical examination, a biopsy is performed to differentiate NL from conditions with similar clinical appearances, including granuloma annulare and necrobiotic xanthogranuloma.

 

If there is a concern for venous disease or peripheral arterial disease, further studies are considered. Baseline blood work, including fasting blood glucose or glycosylated hemoglobin, to screen for diabetes or assess glycemic control in patients known to have diabetes.

Continued in the report…..

 

Ulcerated Necrobiosis Lipoidica Treatment

Treatment of ulcerations in patients with NL is challenging, and relapses occur frequently. No known standardized effective treatment for UNL is available until today. There are several treatment options described in the literature that are not evidence‐based. The ultimate goal of treatment is to control the potentially triggering mechanisms and promote granulation epithelialization of wounds.

 

Treatments for NL have had limited success due either to the unclear pathogenesis of the disease or to significant side effects associated with effective treatments, namely, worsening of diabetes with oral corticoids, renal toxicity with cyclosporine, medullar toxicity with mycophenolate mofetil, and peripheral neuropathy with thalidomide.

Continued in the report…..

Ulcerated Necrobiosis Lipoidica Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of Necrobiosis Lipoidica (NL), diagnosed prevalent cases of NL by Comorbidities and diagnosed prevalent cases of Ulcerated Necrobiosis Lipoidica (UNL) scenario of Ulcerated Necrobiosis Lipoidica (UNL) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total diagnosed prevalent cases of NL in the 7MM was found to be 254,858 in 2021, which might increase up to 2,64,597 in 2032. These cases are expected to increase at a CAGR of 0.4% during study period (2019–2032).
  • The diagnosed prevalent cases of NL were distributed on the basis of comorbidities into Diabetic NL Patients and Non Diabetic NL. As per our estimates, in 2021 the diagnosed prevalent cases of NL were more in Diabetic Patients in the 7MM.
  • The total diagnosed prevalent cases of UNL in the 7MM were observed to be 87,467 in 2021. These cases are expected to increase during the study period (2019–2032).
  • Among 7MM, the United States has the highest prevalent cases of UNL with 49,330 cases in 2021.
  • Among the European countries, Germany had the highest diagnosed prevalent population of UNL with 8,010 cases, followed by Spain with 5,913 cases in 2021. On the other hand, France had the lowest diagnosed prevalent population.
  • In Japan, 9,542 diagnosed prevalent cases of Ulcerated Necrobiosis Lipoidica were recorded in the year 2021.

Country-Wise Ulcerated Necrobiosis Lipoidica Epidemiology

The epidemiology segment also provides the Ulcerated Necrobiosis Lipoidica epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Ulcerated Necrobiosis Lipoidica Drug Chapters

The drug chapter segment of the Ulcerated Necrobiosis Lipoidica report encloses the detailed analysis of UNL marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the UNL clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Ulcerated Necrobiosis Lipoidica Emerging Drugs

 

PCS499: Processa Pharmaceuticals

It is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental) and is being investigated to treat UNL. PCS499 and its metabolites act on multiple pharmacological targets that are important in various conditions. The FDA granted Orphan Drug Designation for PCS499 for the treatment of NL and 7 years of US exclusivity on the FDA approval.

Products detail in the report…

List of products to be continued in the report…

Ulcerated Necrobiosis Lipoidica Market Outlook

Treatment of ulcerations in patients with NL is challenging, and relapses occur frequently. No known standardized effective treatment for UNL is available until today. There are several treatment options described in the literature that are not evidence‐based.

 

The first-line therapies may include topical and intralesional corticosteroids. Smoking cessation and diabetic control may also be effective; nevertheless, there is no correlation between disease activity and glycemic control. Other treatments include systemic corticosteroids, topical tacrolimus, cyclosporine, mycophenolate mofetil, pentoxifylline, fumaric acid esters, clofazimine, antimalarial agents, topical psoralen-UVA, UVA1 phototherapy, photodynamic therapy and excision, and skin grafting.

 

Key Findings

  • The market size of Ulcerated Necrobiosis Lipoidica in seven major markets was USD 35 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 23.1 % for the study period (2019–2032)
  • The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Ulcerated Necrobiosis Lipoidica.
  • Upcoming therapy such as PCS499 has the potential to create a significant positive shift in the Ulcerated Necrobiosis Lipoidica market size.
  • The United States accounts for the largest market size of Ulcerated Necrobiosis Lipoidica, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

 

The United States Market Outlook

This section provides the total Ulcerated Necrobiosis Lipoidica market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Ulcerated Necrobiosis Lipoidica market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Ulcerated Necrobiosis Lipoidica market size and market size by therapies in Japan are provided.

Ulcerated Necrobiosis Lipoidica Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerated Necrobiosis Lipoidica market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Ulcerated Necrobiosis Lipoidica market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Ulcerated Necrobiosis Lipoidica Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Ulcerated Necrobiosis Lipoidica emerging therapies.

Reimbursement Scenario in Ulcerated Necrobiosis Lipoidica

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Ulcerated Necrobiosis Lipoidica market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Ulcerated Necrobiosis Lipoidica, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Ulcerated Necrobiosis Lipoidica epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Ulcerated Necrobiosis Lipoidica is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Ulcerated Necrobiosis Lipoidica market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Ulcerated Necrobiosis Lipoidica market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Ulcerated Necrobiosis Lipoidica market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerated Necrobiosis Lipoidica R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Ulcerated Necrobiosis Lipoidica. The launch of emerging therapies will significantly impact the Ulcerated Necrobiosis Lipoidica market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Ulcerated Necrobiosis Lipoidica Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Ulcerated Necrobiosis Lipoidica Pipeline Analysis
  • Ulcerated Necrobiosis Lipoidica Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Ulcerated Necrobiosis Lipoidica Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Ulcerated Necrobiosis Lipoidica Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Ulcerated Necrobiosis Lipoidica Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Ulcerated Necrobiosis Lipoidica market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Ulcerated Necrobiosis Lipoidica total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Ulcerated Necrobiosis Lipoidica market size during the forecast period (2022–2032)?
  • At what CAGR, the Ulcerated Necrobiosis Lipoidica market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Ulcerated Necrobiosis Lipoidica market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Ulcerated Necrobiosis Lipoidica market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Ulcerated Necrobiosis Lipoidica?
  • What is the historical Ulcerated Necrobiosis Lipoidica patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Ulcerated Necrobiosis Lipoidica at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Ulcerated Necrobiosis Lipoidica?
  • Out of the above-mentioned countries, which country would have the highest population of Ulcerated Necrobiosis Lipoidica during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Ulcerated Necrobiosis Lipoidica along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Ulcerated Necrobiosis Lipoidica in the US and Europe?
  • What are the Ulcerated Necrobiosis Lipoidica marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Ulcerated Necrobiosis Lipoidica?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Ulcerated Necrobiosis Lipoidica?
  • What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Ulcerated Necrobiosis Lipoidica therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ulcerated Necrobiosis Lipoidica and their status?
  • What are the key designations that have been granted for the emerging therapies for Ulcerated Necrobiosis Lipoidica?
  • What are the 7MM historical and forecasted market of Ulcerated Necrobiosis Lipoidica?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Ulcerated Necrobiosis Lipoidica.
  • To understand the future market competition in the Ulcerated Necrobiosis Lipoidica market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Ulcerated Necrobiosis Lipoidica in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Ulcerated Necrobiosis Lipoidica market.
  • To understand the future market competition in the Ulcerated Necrobiosis Lipoidica market.

1. Key Insights

2. Report Introduction

3. Ulcerated Necrobiosis Lipoidica Market Overview at a Glance

3.1. Market Share (%) Distribution of Ulcerated Necrobiosis Lipoidica by Therapies in 2019

3.2. Market Share (%) Distribution of Ulcerated Necrobiosis Lipoidica by Therapies in 2032

4. Ulcerated Necrobiosis Lipoidica Market: Future Perspective

5. Executive Summary of Ulcerated Necrobiosis lipoidica

6. Key Events

7. Disease Background and Overview: Ulcerated Necrobiosis Lipoidica

7.1. Introduction

7.2. Risk Factors, Signs and Symptoms

7.3. Etiology

7.4. Pathophysiology

7.5. Diagnosis

7.6. Treatment and Management

7.6.1. Treatment Algorithm

7.6.2. Treatment Guidelines

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.4. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM

8.5. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM

8.6. The United States

8.6.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States

8.6.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the United States

8.6.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the United States

8.7. Major Five European Countries

8.7.1. Germany

8.7.1.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany

8.7.1.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany

8.7.1.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany

8.7.2. France

8.7.2.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France

8.7.2.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France

8.7.2.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France

8.7.3. Italy

8.7.3.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy

8.7.3.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy

8.7.3.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy

8.7.4. Spain

8.7.4.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain

8.7.4.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain

8.7.4.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain

8.7.5. UK

8.7.5.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK

8.7.5.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK

8.7.5.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK

8.8. Japan

8.8.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Japan

8.8.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan

8.8.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan

9. Patient Journey

10. Emerging Drugs

10.1. PCS499: Processa Pharmaceuticals

10.1.1. Product Description

10.1.2. Development activities

10.1.3. Clinical Development

10.1.4. Clinical Trials Information

10.1.5. Safety and Efficacy

10.1.6. Product Profile

10.1.7. Analyst Views

11. Ulcerated Necrobiosis Lipoidica: Seven Major Market Analysis

11.1. Key Findings

11.2. Market Methodology

11.3. Market Outlook

11.4. Potential of Emerging Therapies

11.5. Key Market Forecast Assumptions

11.6. Market Size of Ulcerated Necrobiosis Lipoidica in the 7MM

11.7. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the 7MM

11.8. United States Market Size

11.8.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.8.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the US

11.9. Major Five European Countries: Market Size

11.9.1. Germany: Market Size

11.9.1.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.9.1.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Germany

11.9.2. France: Market Size

11.9.2.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.9.2.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in France

11.9.3. Italy: Market Size

11.9.3.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.9.3.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Italy

11.9.4.  Spain: Market Size

11.9.4.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.9.4.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Spain

11.9.5. The UK: Market Size

11.9.5.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.9.5.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in The UK

11.10. Japan Market Size

11.10.1. Total Market Size of Ulcerated Necrobiosis Lipoidica

11.10.2. Market Size of Ulcerated Necrobiosis Lipoidica by Therapies

12. Key Opinion Leaders’ Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

18.1. Bibliography

18.2. Report Methodology

18.3. Abbreviation

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Key Events

Table 2: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM (2019–2032)

Table 3: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM (2019–2032)

Table 4: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States (2019–2032)

Table 5: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the US (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the US (2019–2032)

Table 7: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany (2019–2032)

Table 8: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany (2019–2032)

Table 9: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany (2019–2032)

Table 10: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France (2019–2032)

Table 11: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France (2019–2032)

Table 12: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France (2019–2032)

Table 13: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy (2019–2032)

Table 14: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy (2019–2032)

Table 15: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy (2019–2032)

Table 16: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain (2019–2032)

Table 17: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain (2019–2032)

Table 18: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain (2019–2032)

Table 19: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK (2019–2032)

Table 20: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK (2019–2032)

Table 21: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK (2019–2032)

Table 22: Total Prevalent Cases of Necrobiosis Lipoidica in Japan (2019–2032)

Table 23: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan (2019–2032)

Table 24: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan (2019–2032)

Table 25: PCS499, Clinical Trial Description, 2022

Table 26: Key Market Forecast Assumptions for PCS499

Table 27: Total Market Size of Ulcerated Necrobiosis Lipoidica in the 7MM in USD Million (2019–2032)

Table 28: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the 7MM, in USD Million (2019–2032)

Table 29: Total Market Size of Ulcerated Necrobiosis Lipoidica in the US, in USD Million (2019–2032)

Table 30: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the US, in USD Million (2019–2032)

Table 31: Total Market Size of Ulcerated Necrobiosis Lipoidica in the EU-5, in USD Million (2019–2032)

Table 32: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in EU-5, in USD Million (2019–2032)

Table 33: Total Market Size of Ulcerated Necrobiosis Lipoidica in Germany, in USD Million (2019–2032)

Table 34: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Germany, in USD Million (2019–2032)

Table 35: Total Market Size of Ulcerated Necrobiosis Lipoidica in France in USD Million (2019–2032)

Table 36: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in France, in USD Million (2019–2032)

Table 37: Total Market Size of Ulcerated Necrobiosis Lipoidica in Italy in USD Million (2019–2032)

Table 38: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Italy, in USD Million (2019–2032)

Table 39: Total Market Size of Ulcerated Necrobiosis Lipoidica in Spain in USD Million (2019–2032)

Table 40: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Spain, in USD Million (2019–2032)

Table 41: Total Market Size of Ulcerated Necrobiosis Lipoidica in the UK in USD Million (2019–2032)

Table 42: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the UK, in USD Million (2019–2032)

Table 43: Total Market Size of Ulcerated Necrobiosis Lipoidica in Japan, in USD Million (2019–2032)

Table 44: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Japan, in USD Million (2019–2032)

Table 45: Abbreviation

List of Figures

Figure 1: Anterior Aspect of both Legs Showing Large and Ulcerative Plaques of Necrobiosis Lipoidica

Figure 2: Conditions with an increased risk of developing Necrobiosis Lipoidica

Figure 3: Complications of Necrobiosis Lipoidica

Figure 4: Clinical Manifestations and Histopathological Findings

Figure 5: Representative Section of the Patient’s Punch Biopsy

Figure 6: Approach to Necrobiosis Lipoidica

Figure 7: Treatment Options for Necrobiosis Lipoidica

Figure 8: Treatment Algorithm

Figure 9: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM (2019–2032)

Figure 10: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM (2019–2032)

Figure 11: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States (2019–2032)

Figure 12: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the US (2019–2032)

Figure 13: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the US (2019–2032)

Figure 14: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany (2019–2032)

Figure 15: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany(2019–2032)

Figure 16: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany (2019–2032)

Figure 17: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France (2019–2032)

Figure 18: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France (2019–2032)

Figure 19: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France (2019–2032)

Figure 20: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy (2019–2032)

Figure 21: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy (2019–2032)

Figure 22: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy (2019–2032)

Figure 23: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain (2019–2032)

Figure 24: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain (2019–2032)

Figure 25: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain (2019–2032)

Figure 26: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK (2019–2032)

Figure 27: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK (2019–2032)

Figure 28: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK (2019–2032)

Figure 29: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Japan (2019–2032)

Figure 30: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan (2019–2032)

Figure 31: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan (2019–2032)

Figure 32: Patient Journey

Figure 33: Total Market Size of Ulcerated Necrobiosis Lipoidica in the 7MM in USD Million (2019–2032)

Figure 34: Total Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the 7MM in USD Million (2019–2032)

Figure 35: Total Market Size of Ulcerated Necrobiosis Lipoidica in the US, in USD Million (2019–2032)

Figure 36: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the United States, in USD million (2019–2032)

Figure 37: Total Market Size of Ulcerated Necrobiosis Lipoidica in Germany, in USD Million (2019–2032)

Figure 38: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Germany, in USD million (2019–2032)

Figure 39: Total Market Size of Ulcerated Necrobiosis Lipoidica in France, in USD Million (2019–2032)

Figure 40: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in France, in USD million (2019–2032)

Figure 41: Total Market Size of Ulcerated Necrobiosis Lipoidica in Italy, in USD Million (2019–2032)

Figure 42: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Italy, in USD million (2019–2032)

Figure 43: Total Market Size of Ulcerated Necrobiosis Lipoidica in Spain, in USD Million (2019–2032)

Figure 44: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Spain, in USD million (2019–2032)

Figure 45: Total Market Size of Ulcerated Necrobiosis Lipoidica in the UK, in USD Million (2019–2032)

Figure 46: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in the UK, in USD million (2019–2032)

Figure 47: Total Market Size of Ulcerated Necrobiosis Lipoidica in Japan, in USD Million (2019–2032)

Figure 48: Market Size of Ulcerated Necrobiosis Lipoidica by Therapies in Japan, in USD million (2019–2032)

Figure 49: Market Drivers

Figure 50: Market Barriers

Figure 51: SWOT Analysis

Figure 52: Unmet Needs

Processa Pharmaceuticals

 

Forward to Friend

Need A Quote